Teva Pharmaceutical Industries Ltd have sued pre=”sued “>Mylan Inc, alleging that Mylan’s application to market a generic version of glatiramer acetate, infringed certain patents covering the chemical composition of Teva’s multiple sclerosis drug Copaxone, pharmaceutical compositions containing it and methods of using it.
Teva maintains that the patents are enforceable until May 2014. By filing suit, Teva hopes to restrict approval of Mylan’s generic version of drug for up to 30 months.
